Liquidia Corp has agreed to immediately cease and desist all sales of its infringing Yutrepia product for PH-ILD upon receiving FDA approval for an amended product label that removes the indication.
SEC EDGAR, 2026-10-14: 8-K (Item 1.01, 1.02, 7.01, 8.01, 9.01) — "cease and desist"
Liquidia Corp has agreed to immediately cease and desist all sales of its infringing Yutrepia product for PH-ILD upon receiving FDA approval for an amended product label that removes the indication.
Company: Liquidia Corp (LQDA) Filed: 2026-10-14, 8-K (Item 1.01, 1.02, 7.01, 8.01, 9.01) Phrase: "cease and desist" — "Upon such FDA approval, Liquidia shall immediately cease and desist any and all sales of the Infringing Liquidia Product, and shall immediately confirm that it has done so in writing to UTC in accordance with Section 3.1 ." What the filing says: Liquidia entered into a Settlement Agreement with United Therapeutics Corporation (UTC) to resolve their contested patent proceedings. Under the agreement, Liquidia must immediately file with the FDA to amend its Yutrepia (treprostinil) inhalation powder label to remove pulmonary hypertension associated with interstitial lung disease (PH-ILD) as an indicated treatment. Upon FDA approval of this amended label, Liquidia must cease and desist all sales of the infringing product and solely market Yutrepia for Group 1 pulmonary arterial hypertension (PAH). Liquidia also agreed to pay UTC redacted one-time damages for past sales, plus redacted prospective infringement payments in two installments due by January 31, 2027, and April 30, 2027, secured by an irrevocable letter of credit. Two ways it goes: A. The FDA approves the amended label, Liquidia halts PH-ILD sales, and the litigation is dismissed with prejudice. B. The FDA does not approve the amended label, or Liquidia fails to secure the required letter of credit, allowing UTC to terminate the settlement and resume litigation. Next date: January 31, 2027, for the payment of the first prospective infringement installment. Watch: FDA approval of the amended Yutrepia product label removing the PH-ILD indication.